ARCHIVES

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

“Harm-Reduction” Products No Proven, IOM Report Says.

March 2, 2001

Dingell: “Unable To Vouch” For Staff Report On NCI’s Gallo

February 10, 1995

DRCCA Completes New Cancer control Research Guidelines

August 5, 1983

NCI Producing TV Tapes For Black Awareness Program

March 14, 1986

University Of Illinois Cancer Center Director Kruh Dies

January 7, 2011

ONS Award Winners, Grantees, Announced At Annual Congress

July 27, 1990